Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy.

Lowery CD, Blosser W, Dowless M, Renschler M, Perez LV, Stephens J, Pytowski B, Wasserstrom H, Stancato LF, Falcon B.

Oncotarget. 2019 Sep 17;10(53):5523-5533. doi: 10.18632/oncotarget.27148. eCollection 2019 Sep 17.

2.

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.

Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Lin AB, Beckmann RP, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Smith MA, Stancato LF.

Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. doi: 10.1158/1078-0432.CCR-18-2728. Epub 2018 Dec 18.

PMID:
30563935
3.

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.

Gong X, Du J, Parsons SH, Merzoug FF, Webster Y, Iversen PW, Chio LC, Van Horn RD, Lin X, Blosser W, Han B, Jin S, Yao S, Bian H, Ficklin C, Fan L, Kapoor A, Antonysamy S, Mc Nulty AM, Froning K, Manglicmot D, Pustilnik A, Weichert K, Wasserman SR, Dowless M, Marugán C, Baquero C, Lallena MJ, Eastman SW, Hui YH, Dieter MZ, Doman T, Chu S, Qian HR, Ye XS, Barda DA, Plowman GD, Reinhard C, Campbell RM, Henry JR, Buchanan SG.

Cancer Discov. 2019 Feb;9(2):248-263. doi: 10.1158/2159-8290.CD-18-0469. Epub 2018 Oct 29.

PMID:
30373917
4.

Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.

Dowless M, Lowery CD, Shackleford T, Renschler M, Stephens J, Flack R, Blosser W, Gupta S, Stewart J, Webster Y, Dempsey J, VanWye AB, Ebert P, Iversen P, Olsen JB, Gong X, Buchanan S, Houghton P, Stancato L.

Clin Cancer Res. 2018 Dec 1;24(23):6028-6039. doi: 10.1158/1078-0432.CCR-18-1256. Epub 2018 Aug 21.

PMID:
30131386
5.

Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.

Lowery CD, Blosser W, Dowless M, Knoche S, Stephens J, Li H, Surguladze D, Loizos N, Luffer-Atlas D, Oakley GJ 3rd, Guo Q, Iyer S, Rubin BP, Stancato L.

Clin Cancer Res. 2018 Feb 15;24(4):847-857. doi: 10.1158/1078-0432.CCR-17-1258. Epub 2017 Nov 30.

6.

The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.

Lowery CD, VanWye AB, Dowless M, Blosser W, Falcon BL, Stewart J, Stephens J, Beckmann RP, Bence Lin A, Stancato LF.

Clin Cancer Res. 2017 Aug 1;23(15):4354-4363. doi: 10.1158/1078-0432.CCR-16-2876. Epub 2017 Mar 7.

7.

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.

Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.

Oncotarget. 2017 Feb 7;8(6):9251-9266. doi: 10.18632/oncotarget.14002.

8.

LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.

King C, Diaz HB, McNeely S, Barnard D, Dempsey J, Blosser W, Beckmann R, Barda D, Marshall MS.

Mol Cancer Ther. 2015 Sep;14(9):2004-13. doi: 10.1158/1535-7163.MCT-14-1037. Epub 2015 Jul 3.

9.

A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology.

Tate CM, Mc Entire J, Pallini R, Vakana E, Wyss L, Blosser W, Ricci-Vitiani L, D'Alessandris QG, Morgante L, Giannetti S, Larocca LM, Todaro M, Benfante A, Colorito ML, Stassi G, De Maria R, Rowlinson S, Stancato L.

PLoS One. 2015 Apr 28;10(4):e0125697. doi: 10.1371/journal.pone.0125697. eCollection 2015.

10.

A method to assess target gene involvement in angiogenesis in vitro and in vivo using lentiviral vectors expressing shRNA.

Blosser W, Vakana E, Wyss LV, Swearingen ML, Stewart J, Stancato L, Tate CM.

PLoS One. 2014 Apr 23;9(4):e96036. doi: 10.1371/journal.pone.0096036. eCollection 2014.

11.

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.

King C, Diaz H, Barnard D, Barda D, Clawson D, Blosser W, Cox K, Guo S, Marshall M.

Invest New Drugs. 2014 Apr;32(2):213-26. doi: 10.1007/s10637-013-0036-7. Epub 2013 Oct 10.

PMID:
24114124
12.

LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo.

Tate CM, Blosser W, Wyss L, Evans G, Xue Q, Pan Y, Stancato L.

J Biol Chem. 2013 Mar 1;288(9):6743-53. doi: 10.1074/jbc.M112.425553. Epub 2013 Jan 18.

13.

Knockdown of ubiquitin ligases in glioblastoma cancer stem cells leads to cell death and differentiation.

Low J, Blosser W, Dowless M, Ricci-Vitiani L, Pallini R, de Maria R, Stancato L.

J Biomol Screen. 2012 Feb;17(2):152-62. doi: 10.1177/1087057111422565. Epub 2011 Sep 28.

PMID:
21956171
14.

Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization.

Meier T, Uhlik M, Chintharlapalli S, Dowless M, Van Horn R, Stewart J, Blosser W, Cook J, Young D, Ye X, Evans G, Credille K, Ballard D, Huber L, Capen A, Chedid M, Ilaria R Jr, Smith MC, Stancato L.

Mol Cancer Ther. 2011 Nov;10(11):2168-78. doi: 10.1158/1535-7163.MCT-11-0323. Epub 2011 Sep 8.

15.

A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators.

Sutherland JJ, Low J, Blosser W, Dowless M, Engler TA, Stancato LF.

Mol Cancer Ther. 2011 Feb;10(2):242-54. doi: 10.1158/1535-7163.MCT-10-0720. Epub 2011 Jan 7.

16.

Phenotypic fingerprinting of small molecule cell cycle kinase inhibitors for drug discovery.

Low J, Chakravartty A, Blosser W, Dowless M, Chalfant C, Bragger P, Stancato L.

Curr Chem Genomics. 2009 Mar 24;3:13-21. doi: 10.2174/1875397300903010013.

17.

High-content imaging characterization of cell cycle therapeutics through in vitro and in vivo subpopulation analysis.

Low J, Huang S, Blosser W, Dowless M, Burch J, Neubauer B, Stancato L.

Mol Cancer Ther. 2008 Aug;7(8):2455-63. doi: 10.1158/1535-7163.MCT-08-0328.

18.

High-content imaging analysis of the knockdown effects of validated siRNAs and antisense oligonucleotides.

Low J, Shuguang Huang, Dowless M, Blosser W, Vincent T, Davis S, Hodson J, Koller E, Marcusson E, Blanchard K, Stancato L.

J Biomol Screen. 2007 Sep;12(6):775-88. Epub 2007 May 21.

PMID:
17517903
19.

Supplemental Content

Loading ...
Support Center